Tag: metastatic uveal melanoma
Delcath Systems announce first commercial use of Hepzato Kit
Delcath Systems, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has announced the first commercial use...
Delcath Systems announces additional funding for Hepzato Kit FDA approval
Delcath Systems, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has announced that it raised approximately...
Percutaneous melphalan perfusion can induce significant responses in uveal liver metastases
Percutaneous hepatic perfusion with melphalan for the treatment of metastatic uveal melanoma (mUM) offers a hepatic response rate of 66.7% and good progression-free survival...
